Skip to Main Content

Advertisement

Skip Nav Destination
photo of Elaine R. Mardis, PhD photo of Lillian L. Siu, MD

Editors-In-Chief


Elaine R. Mardis, PhD
Nationwide Children's Hospital
The Ohio State University

Lillian L. Siu, MD
Princess Margaret Cancer Centre
University of Toronto

Editors-In-Chief

Elaine R. Mardis, PhD
Nationwide Children's Hospital
The Ohio State University
    
Lillian L. Siu, MD
Princess Margaret Cancer Centre
University of Toronto

Editors' Corner

Toward New Horizons in Cancer Therapeutics

Dr. Mardis and Dr. Siu recap the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics conference and highlight articles in the Therapeutic Research and Development section, headed by Dr. Alex Sparreboom of The Ohio State University.

 

Journal Sections

Cancer Research Communications welcomes high-quality research spanning the full spectrum of cancer science and medicine. This open access journal expands the AACR journal portfolio, stimulates the exchange of new ideas and approaches, and provides a rapid publication pathway. The below sections reflect the breadth of this new journal’s scope.

Featured Articles

Molecular and Cellular Biology
Shino Endo, Yuki Yoshino et al.
Homologous recombination (HR)-deficient cells are sensitive to PARP inhibitors through a synthetic lethal effect. We previously developed an HR activity assay named Assay of Site-Specific HR Activity (ASHRA). Here, we evaluated the HR activity of 30 missense variants of BRCA1 by ASHRA and found that several BRCA1 variants ...
Tumor Biology
Akira Saito, Joji Kitayama et al.
Dipeptidyl peptidase IV inhibitor (DPP-4i) has been shown to act either as a promoter or as a suppressor for cancer. Although epidemiologic studies suggest that DPP-4i does not correlate with the development of malignancies, its effects on cancer metastases are controversial. We evaluated the impact of DPP-4i on ...
Immuno-oncology
C. Alston James, Peter Ronning et al.
Allogeneic cancer vaccines are designed to induce antitumor immune responses with the goal of impacting tumor growth. Typical allogeneic cancer vaccines are produced by expansion of established cancer cell lines, transfection with vectors encoding immunostimulatory cytokines, and lethal irradiation. More than 100 clinical ...
Emerging Technologies and Data Science
C. Alston James, Peter Ronning et al.
Allogeneic cancer vaccines are designed to induce antitumor immune responses with the goal of impacting tumor growth. Typical allogeneic cancer vaccines are produced by expansion of established cancer cell lines, transfection with vectors encoding immunostimulatory cytokines, and lethal irradiation. More than 100 clinical ...
Therapeutic Research and Development
Kyle A. Cottrell, Luisangely Soto-Torres et al.
The RNA editing enzyme ADAR is an attractive therapeutic target for multiple cancers. Through its deaminase activity, ADAR edits adenosine to inosine in double-stranded RNAs. Loss of ADAR in some cancer cell lines causes activation of the type I IFN pathway and the PKR translational repressor, leading to inhibition of ...
Precision Medicine and Biomarkers
Glenn J. Hanna, Alessandro Villa et al.
Oral leukoplakia is common and may, in some cases, progress to carcinoma. Proliferative leukoplakia is a progressive, often multifocal subtype with a high rate of malignant transformation compared with the more common localized leukoplakia. We hypothesized that the immune microenvironment and gene expression patterns ...
Close Modal

or Create an Account

Close Modal
Close Modal